Product Introduction
Bioactivity


英文名: Tremelimumab

描述: Tremelimumab 是一种细胞毒性T淋巴细胞相关抗原-4（CTLA-4）阻断抗体.Tremelimumab 常与 Durvalumab 联合使用来治疗肝癌、肺癌等实体癌。

体外活性: Tremelimumab exhibits a higher binding affinity for CTLA-4-Ig compared to CD28-Ig, demonstrating specificity for cynomolgus monkeys and humans. It does not engage with human leukocyte FcγR, mitigating the risk of cytokine release syndrome. Interestingly, Tremelimumab enhances IL-2 production in a concentration-dependent manner when stimulated with staphylococcal enterotoxin A, showcasing its ability to modulate T-cell responses.[1]

存储条件: store at low temperaturestore at -20°C

关键字: CP 675206 | Tremelimumab | CP675206